Hangzhou Biotest Biotech Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	1,211	1,476	1,591	1,907	1,940	1,368
Short-Term Investments	-	-	47.04	10	-	-
Trading Asset Securities	13.89	13.76	60.26	-	100.06	360.84
Cash & Short-Term Investments	1,225	1,489	1,698	1,917	2,040	1,729
Cash Growth	-19.60%	-12.30%	-11.43%	-6.01%	18.02%	561.86%
Accounts Receivable	70.23	89.37	97.46	61.89	38.82	146.91
Other Receivables	3.3	3.44	4.27	2.8	1.6	8.32
Receivables	73.54	92.81	101.73	64.68	40.42	155.23
Inventory	74.26	69.68	73.4	99.32	135.2	141.7
Prepaid Expenses	-	-	0.68	-	-	-
Other Current Assets	18.62	9.59	3.85	5.37	19.6	7.2
Total Current Assets	1,391	1,661	1,878	2,087	2,235	2,033
Property, Plant & Equipment	582.69	540.87	408.81	261.58	244.68	231.02
Long-Term Investments	109.12	41.67	19.3	2.84	40	40
Other Intangible Assets	273.08	269.31	275.16	208.71	213.71	20.35
Long-Term Deferred Tax Assets	17.39	10.1	11.8	14.44	13.16	3.01
Long-Term Deferred Charges	-	-	-	0.11	0.21	0.29
Other Long-Term Assets	7.93	15.99	9.15	5.08	4.54	104.13
Total Assets	2,382	2,539	2,602	2,580	2,752	2,432

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	75.85	98.67	56.45	58.35	88.72	224.32
Accrued Expenses	10.72	18.61	19.08	20.02	25.94	26.32
Short-Term Debt	0.47	0.49	0.44	0.59	0.35	5.64
Current Portion of Leases	-	-	-	2.45	5.1	2.28
Current Income Taxes Payable	2.87	0	0.02	-	-	39
Current Unearned Revenue	17.51	15.16	7.39	47.16	44.68	18.56
Other Current Liabilities	24.06	25.05	95.23	20.85	6.28	1.44
Total Current Liabilities	131.55	157.98	178.62	149.43	171.08	317.56
Long-Term Debt	99.5	-	-	-	-	-
Long-Term Leases	-	-	-	-	2.19	4.55
Long-Term Unearned Revenue	8.91	10.19	11.17	8.69	6.43	1.25
Long-Term Deferred Tax Liabilities	-	-	-	0.71	1.16	-
Other Long-Term Liabilities	-	-	-	-	8.43	-
Total Liabilities	239.96	168.17	189.79	158.82	189.29	323.36

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	149.33	149.33	106.67	106.67	106.67	106.67
Additional Paid-In Capital	752.57	751.68	790.45	813.33	814.94	814.94
Retained Earnings	1,364	1,486	1,543	1,510	1,638	1,185
Treasury Stock	-127.45	-18.07	-31.61	-14.76	-	-
Comprehensive Income & Other	2.56	1.24	0.94	-0.36	1.21	0.7
Total Common Equity	2,141	2,370	2,409	2,415	2,561	2,107
Minority Interest	0.24	1.47	2.87	5.51	1.04	1.05
Shareholders' Equity	2,142	2,371	2,412	2,421	2,562	2,108
Total Liabilities & Equity	2,382	2,539	2,602	2,580	2,752	2,432

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	100.04	0.49	0.44	3.04	7.64	12.47
Net Cash (Debt)	1,125	1,489	1,698	1,914	2,032	1,716
Net Cash Growth	-26.16%	-12.30%	-11.31%	-5.81%	18.43%	586.22%
Net Cash Per Share	8.08	10.28	11.52	12.83	13.60	14.15
Filing Date Shares Outstanding	153.62	102.38	150.87	146.38	149.33	149.33
Total Common Shares Outstanding	153.62	102.38	150.87	148.7	149.33	149.33
Working Capital	1,260	1,504	1,699	1,937	2,064	1,715
Book Value Per Share	13.94	23.15	15.97	16.24	17.15	14.11
Tangible Book Value	1,868	2,100	2,134	2,207	2,348	2,087
Tangible Book Value Per Share	12.16	20.52	14.15	14.84	15.72	13.97
Buildings	-	285.72	284.05	193.65	194.71	189.13
Machinery	-	96.77	96.17	90.92	81.61	66.19
Construction In Progress	-	229.58	87.23	39.65	9.85	-